Image

Baseline Relative Peripheral Refraction in Myopia Control

Baseline Relative Peripheral Refraction in Myopia Control

Recruiting
6-9 years
All
Phase 2

Powered by AI

Overview

Myopia has become a world concern and its prevalence has increased in recent decades. Myopic defocus has been applied for slowing down the axial elongation and myopia progression, which is mainly based on the theory of simultaneous competing defocus and peripheral optics. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses impose myopic defocus in the central or peripheral retina, with myopia progression being retarded by 50% to 60%. However, the optimal amount of myopic defocus has not yet been determined. Relative peripheral refraction (RPR) is used to indicate the difference between peripheral refraction and central refraction. Previous studies showed that retinal shape determined RPR, and baseline RPR may influence the myopia control efficacy using DIMS lenses on myopic children. It is still unclear if any other unknown factor influenced the final myopia control outcome in these young children with myopic RPR at baseline. Unlike our previous study8 that bias on hyperopic RPR children (myopic RPR, n = 27; hyperopic RPR, n = 52), this study is a case-control study with the same sample size for each RPR group. We will also include younger children who are more prone to have myopic RPR and develop high myopia. The results should provide new insight into the myopia control strategy in early-onset myopic children.

In the current study, we will investigate the influence of baseline RPR in myopia retardation using DIMS lenses among young myopic children.

This will ba a 1-year prospective clinical trial. Through G*Power (version 3.1.9.6) calculation, 80 healthy myopic subjects (40 myopic RPR vs 40 hyperopic RPR) aged 5-9 years should be needed. After screened by inclusion criteria, eligible participants will be assigned to wear DIMS lenses for 1 year (12 months, 8 hour per day, 7 days per week). This study includes 5 visits: Visit 1: baseline, Visit 2: lens dispensing, Visit 3: 2-week follow-up, Visit 4: 6-month follow-up, and Visit 5: 12-month follow-up. All eye examinations will be carried out in the Optometry Research Centre (A137), the School of Optometry, the Hong Kong Polytechnic University. The main data collection, including refractive error, axial length, related ocular parameters will be measured at baseline, 6-month and 1-year visits. At the lens dispensing and 2-week follow-up visits, vision acuity testing and computer scanning of posterior eyes will be measured. New DIMS lens will be replaced and upgraded if the equivalent sphere of refraction (SER) is changed or visual acuity change.

The following data will be statistically analyzed. The primary outcome data include the difference in change in SER with cycloplegia between the myopic and hyperopic RPR from the baseline over 12 months of treatment. Secondary outcomes data include the changes in axial length, peripheral refraction, relative peripheral refraction, the amplitude of accommodation, lag of accommodation, corneal curvature, phoria and stereoacuity.

Eligibility

Inclusion Criteria:

  • Age at enrolment: 6-9 years
  • Spherical equivalent refraction (SER): -0.75 to -5.00 Diopters (D)
  • Astigmatism: -1.50 D or less
  • Anisometropia: 1.50 D or less
  • Spectacle best-corrected monocular visual acuity (VA): 0.00 logMAR or better

Exclusion Criteria:

  • Ocular and systemic abnormalities might affect visual functions or refractive development
  • Prior use of any drugs or optical devices of myopia control treatment.

Study details
    Myopia

NCT06161311

The Hong Kong Polytechnic University

28 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.